logo
  

Inovio Says Preclinical Studies Show INO-4802 Effective Against COVID-19 Variants - Quick Facts

Biotechnology company Inovio Pharmaceuticals Inc. (INO) announced Wednesday that its next-generation Pan-SARS-CoV-2 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses in preclinical models against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant).

These results demonstrate the potential of Inovio's Pan-COVID-19 vaccine to induce cross-reactive immune responses against current and emerging viral variants as either a first-line vaccine, or potentially as a booster for individuals previously immunized with various Wuhan-matched vaccines.

Inovio's Pan-COVID-19 vaccine approach is designed to provide cross-strain protection, immune coverage, reduced susceptibility to escape mutants, and non-restricted geographical use against both known and potentially unknown variants.

Preclinical data with INO-4802 in multiple models revealed both broader and increased levels of neutralizing antibodies against a panel of variants than strain-matched vaccines. Building on this initial work, Inovio plans to conduct Phase 1/2 clinical trials this year with INO-4802.

The next-generation Pan-COVID-19 variant vaccine candidate is expected to enter a global Phase 3 trial this summer.

To create Inovio's Pan-COVID-19 vaccine candidate, variant sequences were identified over a four-month period starting in October 2020 from multiple geographic regions - Brazil, Canada, India, Italy, Japan, Nigeria, South Africa, United Kingdom, and the United States.

The mutations in the spike sequences were aggregated for each region. The sequence results from these regions were then further engineered to determine a common set of overlapping mutations from emerging variations in the COVID spike protein sequences to generate INO-4802.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
Follow RTT